Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular ...

Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui ...

Merck&Co., Inc., an American multinational biopharmaceutical company, has entered into an agreement to acquire the rights to the experimental drug HRS-5346, developed by China's Jiangsu Hengrui ...

(RTTNews) - Merck & Co., Inc. (MRK), a healthcare company, on Tuesday announced signing of an exclusive license agreement for HRS-5346 with Jiangsu Hengrui Pharmaceuticals Co., Ltd. HRS-5346 is an ...

MSD will pay Hengrui Pharma $200m upfront, up to $1.77bn in development, regulatory and commercial milestones, and royalties ...

Merck secures global rights to HRS-5346, an investigational Lp(a) inhibitor, in a deal with Hengrui Pharma worth up to $1.97 billion.

(Yicai) March 26 -- Shares of Hengrui Pharmaceuticals rose after the Chinese firm granted US-Canadian pharma giant Merck ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Merck has signed a licensing deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion for its experimental heart ...